UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a report issued on Monday morning,Benzinga reports. The firm currently has a $25.00 target price on the stock.

A number of other research analysts also recently issued reports on URGN. HC Wainwright reiterated a “buy” rating and set a $64.00 price objective on shares of UroGen Pharma in a report on Tuesday, February 25th. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $38.20.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $10.82 on Monday. The business’s fifty day moving average price is $10.45 and its two-hundred day moving average price is $11.70. UroGen Pharma has a fifty-two week low of $9.03 and a fifty-two week high of $20.70. The stock has a market capitalization of $253.77 million, a price-to-earnings ratio of -3.43 and a beta of 1.12. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analysts’ expectations of $25.25 million. As a group, analysts predict that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

Hedge funds have recently made changes to their positions in the business. Barclays PLC lifted its position in shares of UroGen Pharma by 409.3% in the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after buying an additional 48,040 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock valued at $864,000 after buying an additional 49,318 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after buying an additional 34,248 shares during the last quarter. Vestal Point Capital LP acquired a new stake in shares of UroGen Pharma in the third quarter valued at approximately $5,080,000. Finally, State Street Corp lifted its position in shares of UroGen Pharma by 5.9% in the third quarter. State Street Corp now owns 769,583 shares of the company’s stock valued at $9,774,000 after buying an additional 42,907 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.